ERBB2 and pancreatic neoplasm: Thus, our in vivo data further confirmed that VPA exhibits anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer likely via induction of miRNAs that target the erbB mRNAs.